Sign inJoin waitlistJoin the waitlist

Lyudmila Bazhenova

Professor of Medicine · University of California (San Diego) Medical Center

Credentials: · · ·

History

University of California (San Diego) Medical Center
Present

Medical Oncology
1997–1999
Internal Medicine
1994–1997
Doctor of Medicine
1990–1994

Research

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Molecular Cancer Therapeutics · 2017 · 1,827 citations
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
The Lancet Oncology · 2020 · 1,363 citations
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
New England Journal of Medicine · 2022 · 871 citations

Jorge Nieva
15 papers
Ross Camidge
15 papers
Kelly Bethel
13 papers
Pasi Jänne
12 papers
Shirish Gadgeel
12 papers
Karen Reckamp
11 papers
Razelle Kurzrock
11 papers
Jyoti Patel
9 papers
Sandip Patel
9 papers · 1 as a fellow
Balazs Halmos
8 papers
Lecia Sequist
8 papers
Scott Gettinger
8 papers

Grants

Specialized Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $301.6K · University of California, San Diego
1996–2031
Ading Color to Cancer, Adenovirus and Flow Cytometry to Identify and Capture CTCs
National Cancer Institute · R43
PI · $301K · Nanocellect Biomedical, Inc.
2011–2013

Clinical trials

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
Principal investigator · Terminated · Phase 2
Lyudmila Bazhenova, M.D.
2007–2012
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
Site PI · Not yet recruiting · Phase 1
Sutro Biopharma, Inc.
2026–2028
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Site PI · Recruiting · Phase 1
Sutro Biopharma, Inc.
2025–2028
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2025–2028